Reed, Maraganore to join Takeda’s board
Plus Merck’s Frazier joins Eikon as independent director, and updates from Transgene and Syapse
The board of Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) will nominate Kimberly Reed and John Maraganore as independent external directors at a shareholder meeting on June 29. Reed was chair, president, and CEO of the Export-Import Bank of the United States. Maraganore was CEO and director at Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) for nearly 20 years until December, and has since joined several biotech VC firms, including Arch Venture Partners, RTW Investments and Atlas Venture. He also chairs the advisory council at the n-Lorem Foundation, and advises Overland Pharmaceuticals. If approved, Reed and Maraganore will succeed Toshiyuki Shiga and Shiro Kuniya, who are retiring.
Additionally, the board will nominate Masami Iijima as chair to succeed Masahiro Sakane, who is retiring. Iijima is an external board director and independent officer at SoftBank Group Corp. (Tokyo:9984). All other current board members will be proposed for re-election...